And it depends on you how soon it will be developed
Pharm Exec's latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.
Milestone on Bayer’s path to completing the planned acquisition of Monsanto
Findings Reported at ASHG 2017 Annual Meeting
Yescarta is the second gene therapy product approved in the U.S.